Nonclassical congenital adrenal hyperplasia (NCAH) can lead to the production of excess male hormones. It is usually a mild condition and often doesn’t need to be treated. Nonclassical ...

Congenital adrenal hyperplasia (CAH) is a group of hereditary disorders that affect the adrenal glands. The adrenal glands produce the hormones cortisol and aldosterone. CAH is caused by genetic ...

Congenital adrenal hyperplasia is a condition that causes the adrenal glands to produce too much androgen, the male sex hormone. This may result in early puberty and other symptoms.

BOSTON — Crinecerfont, an investigational oral selective corticotropin-releasing factor type 1 receptor antagonist, benefits both adults and children with congenital adrenal hyperplasia (CAH ...

References: Neurocrine Biosciences announces FDA approval of Crenessity™ (crinecerfont), a first-in-class treatment for children and adults with classic congenital adrenal hyperplasia.

Children with congenital adrenal hyperplasia have an increased risk for overweight or obesity compared with healthy children, but rates of persistent obesity may be lower than previously thought ...

Orlando, Florida — New data add to the evidence supporting use of crinecerfont for the treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, in both adults and ...

SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to ...

Congenital adrenal hyperplasia is one of the most prevalent genetic endocrine diseases. A new guideline from the Endocrine Society offers expert opinion and evidence-based recommendations on the ...

Study shows crinecerfont aids patients with congenital adrenal hyperplasia. Crinecerfont results in a greater decrease from baseline in the mean daily glucocorticoid dose among patients with ...

CRF1 receptor antagonists in congenital adrenal hyperplasia: A systematic review and meta-analysis of phase 2 open-label and phase 3 clinical trials, Endocrine and Metabolic Science, 18, (100247 ...